https://www.reuters.com/world/china/china-will-not-waver-its-dynamic-clearing-covid-19-strategy-health-commission-2022-11-05/
What’s Going On With Pfizer On Thursday? Pharma Giant’s Shares Tick Lower
Pfizer Inc. reported that its Phase 3 CIFFREO study on Duchenne muscular dystrophy (DMD) gene therapy did not meet its primary effectiveness goal. Despite efforts to improve motor functions in boys aged 4 to 7 using a modified human dystrophin gene, the trial showed no significant progress, affecting Pfizer's quest for new treatments as it diversifies beyond its COVID-19 portfolio.
